Conservative management of delayed, multicomponent coagulopathy following rattlesnake envenomation

Clinical Toxicology

Volumn 43, Issue 3, 2005, Pages 201-206

  Camilleri, Christopher ^a,b,c   Offerman, Steven ^a   Gosselin, Robert ^d   Albertson, Timothy ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^c California Poison Control System   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antivenom; Coagulopathy; CroFab; Crotaline envenomation; Rattlesnake bite

Indexed keywords

BICARBONATE; CHLORIDE; CREATININE; CROTALINE FAB; CROTALINE POLYVALENT IMMUNOGLOBULIN F(AB) FRAGMENT; FIBRINOGEN; GLUCOSE; HEMOGLOBIN; IMMUNOGLOBULIN F(AB) FRAGMENT; MORPHINE; POTASSIUM; SNAKE VENOM ANTISERUM; SODIUM; UNCLASSIFIED DRUG; SNAKE VENOM; THROMBOPLASTIN;

ADULT; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CASE REPORT; CONSERVATIVE TREATMENT; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFECT; ENVENOMATION; ERYTHEMA; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; OBSERVATION; PAIN; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; RISK FACTOR; SKIN EDEMA; SNAKE; THROMBOCYTE COUNT; CLINICAL FEATURE; DELAYED HYPERSENSITIVITY; DISEASE COURSE; DRUG TREATMENT FAILURE; GENERAL CONDITION IMPROVEMENT; LABORATORY TEST; MEDICAL ASSESSMENT; PATIENT TRANSPORT; SNAKEBITE;

SERPENTES;

EID: 18744414503     PISSN: 07313810     EISSN: 10979875     Source Type: Journal    
DOI: 10.1081/CLT-200053339     Document Type: Article

References (15)

1. Ruha A, Curry SC, Beuhler M, Katz K, Brooks DE, Graeme KA, Wallace K, Gerkin R, LoVecchio F, Wax P, Selden B. Initial postmarketing experience with crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation. Ann Emerg Med 2002; 39(6): 609-615.
2. Tanen DA, Ruha A, Graeme KA, Curry SC. Epidemiology and hospital course of rattlesnake envenomations cared for at a Tertiary Referral Center in Central Arizona. Acad Emerg Med 2001; 8(2):177-182.
3. Dart RC, McNally J. Efficacy, safety and use of snake antivenoms in the United States. Ann Emerg Med 2001; 37(2):181-188.
4. Protherics PLC. Crotalidae Polyvalent Immune Fab. Available at: http://www.protherics.com/wprod_cro.html. Accessed March 30, 2004.
5. Guisto JA. Severe toxicity from crotalid envenomation after early resolution of symptoms. Ann Emerg Med 1995; 26(3):387-389.
6. Bogdan GM, Dart RC, Falbo SC, Mcnally J, Spaite D. Recurrent coagulopathy after antivenom treatment of crotalid snakebite. South Med J 2000; 93(6):562-566.
7. Boyer LV, Siefert SA, Clark RF, Mcnally JT, Williams SR, Nordt SP, Walter FG, Dart RC. Recurrent and persistent coagulopathy following pit viper envenomation. Arch Intern Med 1999; 159:706-710.
8. Meier J, Stocker K. Effects of snake venoms on hemostasis. Crit Rev Toxicol 1991; 21(3):171-182.
9. Ouyang C, Teng CM, Huang TF. Characterization of snake venom components acting on blood coagulation and platelet function. Toxicon 1992; 30(9):945-966.
10. Henschen-Edman AH, Theodoe I, Edwards BFP, Pirkle H. Crotalase, a fibrinogen-clotting snake venom enzyme: primary structure and evidence for a fibrinogen recognition exosite different from thrombin. Thromb Haemost 1999; 81:81-86.
11. Bajwa SS, Markland FS, Russell FE. Fibrinolytic enzyme(s) in western diamondback rattlesnake (crotalus atrox) venom. Toxicon 1980; 18:285-290.
12. Budzynski AZ, Pandya BV, Rubin RN, Brizuela BS, Soszka T, Stewart GJ. Fibrinogenolytic afibrinogenemia after envenomation by western diamondback rattlesnake (crotalus atrox). Blood 1980; 63(1):1-14.
13. Hardy DL. Fatal rattlesnake envenomation in Arizona: 1969-1984. J Toxicol Clin Toxicol 1986; 24(1):1-10.
14. Yip L. Rational use of crotalidae polyvalent immune Fab (ovine) in the management of crotaline bite. Ann Emerg Med 2002; 39(6):648-650.
15. Boyer LV, Seifert SA, Cain JS. Recurrence phenomena after immunoglobulin therapy for snake envenomations: part 2. Guidelines for clinical management with crotaline fab antivenom. Ann Emerg Med 2001; 37(2):196-201.